Multiple binomial logistic regression analysis to predict 30-day mortality.

<p>Patients with serum MDA higher than 2.27 nmol/mL (n = 23) presented higher 30-day mortality (Hazard ratio = 2.9; 95% CI = 1.31–6.33; p = 0.005) than patients with lower levels (n = 27) in the survival analysis (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125893#pone.0125893.g003" target="_blank">Fig 3</a>).</p><p>Multiple binomial logistic regression analysis to predict 30-day mortality.</p

Clinical and biochemical characteristics of 30-day survivor and non-survivor MMCAI patients.

<p>P 25–75 = percentile 25^th-75^th; APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; GCS = Glasgow Coma Scale; INR = international normalized ratio; PaO₂ = pressure of arterial oxygen/fraction inspired oxygen; FIO₂ = pressure of arterial oxygen/fraction inspired oxygen; MDA = Malondialdehyde</p><p>Clinical and biochemical characteristics of 30-day survivor and non-survivor MMCAI patients.</p

Characteristics of healthy controls and patients with severe malignant middle cerebral artery infarction.

<p>Characteristics of healthy controls and patients with severe malignant middle cerebral artery infarction.</p

Receiver operation characteristic analysis using serum malondialdehyde levels as predictor of mortality at 30 days.

<p>Receiver operation characteristic analysis using serum malondialdehyde levels as predictor of mortality at 30 days.</p

Serum malondialdehyde levels in severe malignant middle cerebral artery infarction patients and healthy controls.

<p>Serum malondialdehyde levels in severe malignant middle cerebral artery infarction patients and healthy controls.</p

Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.

<p>Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.</p

Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.

<p>Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.</p

Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.

<p>Data are shown as median (percentile 25^th-75^th) or number (%); APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; CCCK = caspase-cleaved cytokeratin; CPP = cerebral perfusion pressure; ICP = intracranial pressure; INR = international normalized ratio; ISS = Injury Severity Score; PaO₂ = pressure of arterial oxygen; FIO₂ = fraction inspired oxygen; PaCO₂ = pressure of arterial carbon dioxide</p><p>Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.</p

Multiple binomial logistic regression analysis to predict 30-day mortality.

<p>GCS Glasgow Coma Scale; CCCK = caspase-cleaved cytokeratin; APACHE II = Acute Physiology and Chronic Health Evaluation</p><p>Multiple binomial logistic regression analysis to predict 30-day mortality.</p

Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.

<p>Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.</p